supported by the Heart and Estrogen/ progestin Replacement Study (HERS), which also tested CEE plus MPA in women with known coronary artery disease at baseline. 9 Despite the early termination of the WHI estrogen plus progestin trial, the WHI estrogen-alone trial was continued with ongoing careful scrutiny by an independent data and safety monitoring board (DSMB) because the health risks and benefits had not been adequately determined. In February 2004, the National Institutes of Health (NIH) decided to terminate the intervention phase of the estrogen-alone study, prior to the scheduled close-out interval of October 2004 to March 2005 . This report presents the results of the estrogenalone trial using available data through February 29, 2004 , prior to notifying participants of the decision on March 1, 2004 . Subsequent detailed reports will include additional outcomes occurring between the participants' last routine follow-up and the date of trial termination. An ancillary study of dementia and cognitive function will be reported separately. Two remaining components of the WHI clinical trial, testing the effects of a low-fat eating pattern and, independently, the effects of calcium plus vitamin D supplementation, are continuing.
METHODS

Study Population and Randomization
Detailed eligibility criteria and recruitment methods have been published. 7, 10 Briefly, most participants were recruited by population-based direct mailing campaigns to age-eligible women, in conjunction with local and national media awareness programs. Women were eligible if they were 50 to 79 years old at initial screening, had undergone hysterectomy (thereby considered postmenopausal for enrollment purposes), and were likely to reside in the area for 3 years. Major exclusions were related to competing risks (any medical condition likely to be associated with a predicted survival of Ͻ3 years), safety (eg, prior breast cancer, other prior cancer within the last 10 years except nonmelanoma skin cancer), adherence and retention concerns (eg, alcoholism, dementia, and transportation problems), or the clinical judgment of the participant's health care practitioner to continue hormone therapy in symptomatic or osteoporotic women. A 3-month washout period was required of women using postmenopausal hormones at initial screening. Prior to the 1997 HERS report, 11 which led to a change in eligibility criteria, 171 women with a history of venous thromboembolism (VTE) were enrolled. The protocol and consent forms were approved by the institutional review board for each participating institution (see the end of this article), and all women provided written informed consent.
Eligible women were randomly assigned to receive 0.625 mg/d of CEE (Premarin; Wyeth, St Davids, Pa) or a matching placebo, in equal proportions. The computerized randomization and blinding procedures have been described. 12 A small imbalance in the number of women in each group was a consequence of an early protocol change eliminating a CEE-alone intervention in women with a uterus. 
Follow-up and Data Collection
Study participants were contacted by telephone 6 weeks after randomization to assess symptoms and reinforce adherence. Follow-up contacts by telephone or clinic visit occurred every 6 months, with clinic visits required annually. At each contact, adherence to study medication was assessed, and information on symptoms, safety concerns, and outcomes was collected. Electrocardiograms were recorded at baseline and at visit years 3, 6, and 9. Annual mammograms and clinical breast examinations were required; study medication was withheld if these safety procedures were not performed or the results could not be verified. Participants were followed up from the date of entry until death, loss to follow-up, or the time of a request for no further contact, regardless of their adherence to study medication. Baseline and year 1 lipid levels were measured in fasting blood specimens from a random 8.6% subsample of women. Methods for subsampling, data collection and management, and quality assurance have been published.
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Maintenance/Discontinuation of Study Medications
During the trial, women with intolerable symptoms such as breast tenderness were managed by reducing the number of days per week that study medication was taken. Participants and study personnel remained blinded when these adjustments were made. Study medication was withheld in participants experiencing a myocardial infarction (MI), stroke, fracture or major injury involving hospitalization, surgery involving use of anesthesia, any illness resulting in immobilization for longer than 1 week, or any other severe illness in which hormone use was considered inappropriate. The decision to resume study medication after MI or stroke was left to the discretion of the clinical center, individual participant, and her health care clinician. Study medication was permanently discontinued in women who developed breast cancer; deep vein thrombosis (DVT) or pulmonary embolism (PE); malignant melanoma; meningioma; triglyceride level higher than 1000 mg/dL (Ͼ11.3 mmol/L); or who were treated by their personal health care practitioners with prescription estrogen, testosterone, or selective estrogen receptor modulators.
Outcome Ascertainment
Designated outcome events were evaluated by review of medical records by centrally trained physician adjudicators at each clinical center who were blinded to treatment assignment and symptoms related to study medication. Cancer. All cancers other than nonmelanoma skin cancers were confirmed by pathology reports, available for 98.2% of invasive breast, 95.0% of colorectal, and 80.6% of other cancers.
Fractures. All reported clinical fractures other than those of the ribs, chest/ sternum, skull/face, fingers, toes, and cervical vertebrae were verified by review of radiology, MRI, or operative reports. WHI investigators did not obtain spine radiographs to ascertain subclinical vertebral fractures.
Global Index. A global index of risks and benefits was defined for each woman as the time to the first event among the monitored outcomes (CHD, stroke, PE, breast cancer, colorectal cancer, hip fractures, and death).
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Statistical Power and Analyses
The trial design assumed 12375 women would need to be randomized to achieve 81% power to detect a 21% reduction in CHD rates over the projected 9-year average follow-up. This sample size would provide 65% power to detect a 20% reduction in hip fracture rates. An additional 5 years of follow-up without intervention was planned to achieve 79% power to detect a 22% increase in breast cancer risk. 7 Calculations based on the observed sample size and age distribution gave power estimates of 72%, 55%, and 71% for CHD, hip fracture, and breast cancer, respectively.
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Lack of adherence to study medication was summarized at each follow-up year as the cumulative proportion of randomized participants who had stopped taking study medications (dropouts) and similarly the proportion of women who began taking prescription menopausal hormones through their own health care practitioner (drop-ins), after excluding preceding deaths. Participants were classified by their most recent status with regard to study medications (stopped or not). Thus, women who temporarily stopped taking study medication were considered adherent in this analysis.
Event rate comparisons were based on the intent-to-treat principle using failure time methods. For a given outcome, the time of event was defined to be the number of days from randomization to the first postrandomization diagnosis of the designated event. For silent MIs, the date of the follow-up electrocardiogram was used as the event date. Follow-up time was censored at the time of the last documented follow-up contact or death. Comparisons of primary outcomes are presented as hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazard analyses, 15 stratified by age, prior disease, and randomization status in the low-fat diet trial. Cumulative hazard rates were estimated by the Kaplan-Meier method for each designated outcome.
Two forms of CIs were calculated, nominal and adjusted. This report primarily presents the nominal 95% CIs because they provide traditional estimates of variability and, as such, are comparable to most other reports of hormone therapy studies. To acknowledge multiple testing issues, adjusted CIs were calculated using group sequential methods, and for secondary outcomes a Bonferroni correction based on the data and safety monitoring plan (see below). Because the trial was nearing the planned termination, the impact of the group sequential adjustment on the width of the CIs is small. The Bonferroni correction reflects the study design and trial monitoring priorities and hence may be somewhat less relevant for interpreting the trial results. Unless otherwise indicated, all CIs and P values are nominal. Statistical analyses were performed using SAS version 9.0 (SAS Institute, Cary, NC) and significance was set at the .05 level.
The possibility of important subgroup effects was explored by testing for interactions in expanded Cox models. Because 23 interactions are reported, chance alone could produce a significant interaction at the .05 level for approximately 1 factor in the series. Sensitivity analyses were conducted to explore the possible impact of lack of adherence to study medications. In these "complier" analyses, the randomization assignment was preserved but follow-up for a woman was censored 6 months after she first became nonadherent (defined as taking Ͻ80% of study pills).
Data and Safety Monitoring
Statistical monitoring boundaries were based on O'Brien-Fleming group sequential procedures 16 with asymmetric boundaries for benefit (1-sided .025-level upper boundary for CHD) and adverse effects (1-sided .05-level lower boundary). The adverse effect boundary for the 6 monitored outcomes of CHD, stroke, PE, hip fractures, colorectal cancer, and death from causes other than the monitored disease outcomes incorporated a Bonferroni correction. The Bonferroni correction was not applied to breast cancer because it was the primary safety outcome. Early stopping was to be EFFECTS OF POSTMENOPAUSAL ESTROGEN ©2004 American Medical Association. All rights reserved.
(Reprinted) JAMA, April 14, 2004 -Vol 291, No. 14 1703 considered if a disease-specific boundary was crossed and the global index was supportive of the overall direction of CEE effects. Formal monitoring of disease rate comparisons began in the fall of 1997 with trial termination planned for March 2005. Additional aspects of the monitoring plan have been published.
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RESULTS
Trial Monitoring and Early Stopping
In early 2000 and again in 2001, after reviewing the data from the estrogenalone and the estrogen plus progestin trials, the DSMB recommended that participants in both trials be informed of early increases in rates of heart disease, strokes, and blood clots in women taking active hormone pills. In 2002, with the early termination of the estrogen plus progestin trial, participants in the estrogen-alone trial were informed that no increase in breast cancer rates had been observed at that point in women taking CEE. The DSMB continued to closely monitor the estrogenalone trial. The DSMB's review of the data for the 13th planned interim analysis through August 31, 2003 , plus an unplanned analysis using data through November 30, 2003 , did not lead to a consensus recommendation. None of the predefined stopping boundaries had been crossed, although the stroke comparison was approaching the adverse effect boundary.
On February 2, 2004 , following subsequent reviews with additional advisors, the NIH decided to stop the intervention phase of the trial. The NIH concluded that with an average of nearly 7 years of follow-up completed, CEE does not appear to affect the risk of heart disease, the primary outcome of the study. Furthermore, the NIH found an increased risk of stroke that was similar to the risk reported from the estrogen plus progestin trial. Recognizing the risk of stroke, and the likelihood that neither cardioprotection nor breast cancer risk would be demonstrated in the remaining intervention period, the NIH deemed it unacceptable to subject healthy women in a prevention trial to this risk. 17 On March 1, 2004, participants were informed of the trial termination and advised to stop taking their study medication. Data available through February 29, 2004 , by routine data collection are included in this report.
Baseline Characteristics
Between 1993 and 1998, a total of 10739 women were randomized into the estrogen-alone trial. Demographic characteristics, medical history, and health behaviors of these women have been described in considerable detail. 18 In general, study participants were healthy and at average risk of CHD and breast cancer, although 441 (4.1%) with prior MI or coronary revascularization were enrolled. The intervention groups were well balanced at baseline on key demographic and disease risk factor characteristics (TABLE 1 and  TABLE 2) .
Follow-up, Adherence, and Unblinding
Vital status is known for 10176 (94.8%) of randomized participants, including 580 (5.4%) known to be deceased. Over the average 6.8 years of follow-up (range, 5.7-10.7 years), only 563 women (5.2%) withdrew, were considered lost to follow-up, or had stopped providing outcomes information for more than 18 months (FIGURE 1) .
At the time of study termination, 53.8% of women had already stopped taking study medication. Dropout rates exceeded design projections, particularly early on, but did not differ significantly by randomization assignment and were stable after year 1, even with the termination of the estrogen plus progestin trial (FIGURE 2). Some women initiated hormone use through their own health care clinician: 5.7% of women in the CEE group and 9.1% in the placebo group by follow-up year 6. These drop-in rates in the placebo group were also somewhat greater than expected. Reasons for initiating hormone therapy outside of the study were not captured. Unblinding of the study gynecologist to randomization assignment was infrequent, occurring for only 100 women in the CEE group and 83 in the placebo group. Per protocol, the treatment assignment was not revealed to other study staff members or the study participants.
Intermediate Cardiovascular Disease End Points
Fasting blood lipid levels, assessed in an 8.6% subsample of women at baseline and year 1, showed a greater reduction in low-density lipoprotein cholesterol (−13.7% vs -1.0%, PϽ.001) and a larger increase in high-density lipoprotein cholesterol (15.1% vs 1.1%, PϽ.001) in the CEE group compared with the placebo group. Reductions in total cholesterol from baseline to year 1 were comparable (−2.3% vs −1.4%, P = .41). Larger increases in triglyceride levels at year 1 were observed in the CEE group than in the placebo group (25.0% vs 3.0%, PϽ.001) . Systolic blood pressure at 1 year was higher by a mean (SE) of 1.1 (0.4) mm Hg in women taking CEE than in women taking placebo (P = .003) and remained similarly elevated throughout followup. Diastolic blood pressures did not differ significantly between the study groups (data not shown).
Clinical Outcomes
Cardiovascular Disease. The primary outcome for this trial was the rate of CHD. The observed CHD incidence rate of 51 per 10000 person-years was 15% lower than projected in the design. No significant effect of CEE was observed on CHD rates compared with placebo CEE did not significantly affect total mortality rates or cause-specific mortality (TABLE 4) .
Time Trends
Differences in cumulative hazards for stroke and to a lesser extent for hip fracture began to emerge early in the intervention period and persisted throughout follow-up (FIGURE 3) . Cumulative breast cancer hazard rates appeared to separate beginning in year 2. Similar displays for the global index and death (FIGURE 4) reinforce the comparability of these rates across treatment groups. Tests for trends with time since randomization were computed for all of the monitored and composite outcomes using a Cox proportional hazards model with a time-dependent treatment interaction term. Coronary heart disease was the only outcome with a statistically significant trend (P = .02) of slightly elevated HRs in the early follow-up period that diminished over time (year 1, 1.16; year 2, 1.20; year 3, 0.89; year 4, 0.79; year 5, 1.28; year 6, 1.24, and year Ն7, 0.42) .
Further Analyses
Exploratory analyses were conducted to determine whether selected participant characteristics modified CEE effects on major clinical outcome event rates. There were no significant interactions between CEE and race/ 
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Of particular interest for all outcomes was age at enrollment (FIGURE 5). The only treatmentϫage interaction reaching statistical significance was for colorectal cancer (P = .048), for which increasing age was associated with increasing risk with CEE use. The effect of prior disease on cardiovascular event rates was also evaluated. Among the 441 women enrolled with prior MI or revascularization procedures, the effect of CEE relative to placebo (33 vs 31; HR, 1.04; 95% CI, 0.63-1.71) did not differ significantly from the CEE effect in women without documented CHD (143 vs 162; HR, 0.91; 95% CI, 0.73-1.14) (P = .55). Similarly, in 168 women reporting prior stroke, the HR for subsequent stroke (6 vs 6; HR, 1.67; 95% CI, 0.52-5.36) did not differ from the HR in women without a history of stroke (152 vs 112; HR, 1.39; 95% CI, 1.09-1.78) (P = .77). Removing from analysis the few participants with a history of PE did not alter the hazard ratio for PE substantially (47 vs 37; HR, 1.31; 95% CI, 0.85-2.01).
Sensitivity analyses were conducted to provide an indication of the potential impact of lack of adherence to assigned study medication. Compared with the primary intent-to-treat analyses (Table 3) , the "complier" models estimated greater risks of stroke (HR, 1.74), pulmonary embolism (HR, 1.99), and total mortality (HR, 1.26) but lower risks of breast cancer (HR, 0.65), hip fracture (HR, 0.48), and colorectal cancer (HR, 0.92). The HRs for CHD (HR, 0.89) and the global index (HR, 1.06) were essentially unchanged.
COMMENT
The WHI estrogen-alone study was a large-scale, randomized, doubleblind, placebo-controlled trial designed to test the effects of the most commonly used postmenopausal hormone therapy preparation in the United States 19 on chronic disease incidence in a diverse population of mostly healthy postmenopausal women aged 50 to 79 years. As conceived, the study had adequate power to detect moderate effects on CHD, hip fractures, and with longer-term follow-up, breast cancer among women across the broad age range relevant for disease prevention hypotheses. This trial demonstrated that CEE increases the risk of stroke, reduces the risk of hip and other fractures, but does not significantly affect the incidence of CHD (the primary outcome) or overall mortality. A nonsignificant reduction in breast cancer incidence requires additional investigation. These observed risks and benefits of CEE for chronic disease rates appear to be balanced over an average 6.8-year follow-up period.
The lack of effect of CEE on CHD risk is substantially different from the favorable reports from observational studies that motivated this trial, and was observed despite an improvement in cholesterol levels. However, these results are consistent with several recent secondary prevention trials that showed no benefit of hormone therapy on atherosclerosis or clinical events. [20] [21] [22] [23] [24] The current study suggests that younger women who use CEE may be at reduced risk of CHD but this possible association may be due to chance.
These CHD results for CEE also differ importantly from 2 previous trials of estrogen plus progestin. In both the WHI estrogen plus progestin trial 25 and HERS, 26 the risk of CHD was significantly elevated in the first year of treatment and the cumulative effects of estrogen plus progestin never appeared beneficial. In the current study, a smaller, nonsignificant increase was observed in the first year of CEE exposure but the cumulative effect suggests a possible modest benefit with longer-term use. Potential explanations for this discrepancy include the role of progestin, differences in the study populations in baseline risk factors, 18 duration of intervention and follow-up time, and the role of chance.
The observed adverse effect of CEE on the risk of stroke is consistent with the risks reported by the WHI and HERS estrogen plus progestin trials. 27, 28 In addition, the use of estradiol in women after ischemic stroke resulted in no change in mortality but a higher rate of recurrent nonfatal stroke and a suggestion of more severe functional deficits. 29 The small but persistent increase in systolic blood pressure in women taking CEE is one possible contributor to this effect because relatively small differences in systolic blood pressure have been positively associated with differences in stroke and cardiovascular disease rates. 30, 31 The WHI estrogen-alone trial provides strong evidence that CEE reduces the risk of hip, clinical vertebral, and other fractures. These reductions were of similar magnitude to those observed in the WHI estrogen plus progestin trial 32 and are consistent with findings from prior observational studies 33, 34 and recent meta-analyses. [35] [36] [37] The trend toward a reduction in breast cancer incidence was unanticipated and is opposite of that observed in the WHI estrogen plus progestin trial, which reported a 24% increased risk. 38 These results also appear contrary to the preponderance of observational study results, 4, 39 including those from the recent Million Women Study. 40 When examining breast cancer risk by type of hormone therapy, most of these studies have reported a modest increase in breast cancer risk with estrogen alone but a greater risk for estrogen plus progestin. Still others have recently found little or no effect of estrogen alone on breast cancer risk. 41 Differences in breast cancer screening between the CEE and placebo groups do not explain the observed breast cancer effects because the WHI protocol mandated annual mammography and clinical breast examinations. The possibility that diagnostic delay could account for this reduction seems remote because the effect of CEE alone on breast density is minimal. 42 Longerterm effects of CEE on breast cancer risk remain uncertain. Extended followup, as is currently planned, and analyses of breast cancer characteristics similar to those reported for the estrogen 
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In preliminary subgroup analyses, the estimated HRs for CEE for several monitored outcomes, including the global index, were lower for women aged 50 to 59 years, although differences in HRs across age groups were not statistically significant. While these results suggest that CEE may be somewhat more favorable in younger than in older women, these subgroup analyses must be interpreted with caution; we cannot exclude the role of chance or limited power.
Limitations
This trial was designed to test only one unopposed estrogen preparation at a single dose, administered orally. We cannot determine whether these results would apply to other formulations, doses, or routes of administration. Care is needed in making comparisons of these estrogen-alone trial results to those of the estrogen plus progestin trial, even though this is of considerable interest. The differences between these 2 study populations in their baseline characteristics, 18, 43 their event rates, the length of intervention and follow-up time, and the completeness of data at this initial report are sufficient to make simple contrasts potentially misleading. More detailed analyses of these parallel trials are planned.
The high rates of discontinuation of study medications and higher than expected crossover from placebo to active hormone use are further limitations. The rate of discontinuation is less than what is usually observed in clinical practice 44 and was similar in the 2 groups. The somewhat higher drop-in rate in the placebo group is not explained by unblinding, which was infrequent (1.5%) and similar in the 2 groups. Sensitivity analyses suggest that the lack of adherence to assigned study medication may have diluted the CEE effects, both positive and negative, relative to what might be observed with full adherence, but it did not distort the overall balance of effects.
Lower than anticipated event rates for some outcomes, particularly CHD and hip fractures, reduce the power relative to what was originally projected but reinforce the generally healthy status of these participants. The fact that the trial was stopped early further decreases the precision of the estimated effects. A longer intervention period may have provided stronger statistical evidence of CEE effects, particularly for CHD, for which some evidence of a trend with time was observed, and for breast cancer, for which the cumulative effect of long-term exposure remains uncertain. Additional data could have allowed for more informative subgroup analyses. Extended follow-up of these women without further intervention is planned.
Clinical Implications
In women aged 50 to 79 years reporting a prior hysterectomy, CEE did not affect CHD rates but did increase the risk of stroke, accounting for an excess risk of 12 cases per 10000 person-years, and reduced the risk of hip fractures, resulting in 6 fewer cases per 10000 personyears. Unexpectedly, women taking CEE also appeared to be diagnosed as having breast cancer at a lower rate than women taking placebo, but the estimated 7 fewer cases per 10000 personyears did not reach statistical significance. The totality of monitored effects, as summarized in the prespecified global index, suggests an overall balance of risks and benefits and importantly no effect on total mortality.
Based on these findings, women and their health care professionals now have usable risk estimates for the benefits and harms of CEE alone. Women considering taking CEE should be counseled about an increased risk of stroke but can be reassured about no excess risk of heart disease or breast cancer for at least 6.8 years of use. At present, these data demonstrate no overall benefit of CEE for chronic disease prevention in postmenopausal women and thus argue against its use in this setting. Overall, these data support the current US Food and Drug Administration recommendations for postmenopausal women to use CEE only for menopausal symptoms at the smallest effective dose for the shortest possible time. 45 
